Nowtransit sells 40,000 Series A convertible preferred shares for $40,000 gross proceeds

BioScience Health Innovations, Inc.

Sold 40,000 Series A convertible preferred shares at $1.00/share to an accredited investor, raising $40,000 gross before expenses.
Each Series A share converts into 3 shares of common stock at holder's election, subject to 4.99% beneficial ownership limitation.
The 4.99% limitation may be increased to 9.99% upon 61 days' notice.
Proceeds will be used for working capital and general corporate purposes (implied).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BioScience Health Innovations, Inc. entered into Stock Purchase Agreement with an accredited investor valued at $40,000 (effective 2022-11-22).

Action: entry
Agreement: equity purchase
Counterparty: an accredited investor
Value: $40,000
Effective: 2022-11-22

Exact text from the filing

On November 22, 2022, Nowtransit Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Agreement”) with an accredited investor pursuant to which the Company sold to the purchaser 40,000 shares of the Company’s Series A Convertible Preferred Stock (the “Series A”) at a purchase price of $1.00 per share (the “Offering”).

View on SEC.gov

Browse all material agreements →

BioScience Health Innovations, Inc. filing history →

Source: SEC EDGAR

accession 0001185185-22-001369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.